Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;10(1):e87-e92.
doi: 10.1055/s-0040-1705173. Epub 2020 Mar 16.

Abortion for Fetal Genetic Abnormalities: Type of Abnormality and Gestational Age at Diagnosis

Affiliations

Abortion for Fetal Genetic Abnormalities: Type of Abnormality and Gestational Age at Diagnosis

Tracy B Grossman et al. AJP Rep. 2020 Jan.

Abstract

Background Advances in genetic screening can identify patients at high risk for common genetic conditions early in pregnancy and can facilitate early diagnosis and early abortion. Less common abnormalities might only be diagnosed with invasive testing is performed after structural abnormalities are identified. Objective Our objective was to compare gestational age (GA) at diagnosis and abortion for genetic abnormalities identified based on screening with abnormalities that were not discovered after screening. Study Design All prenatal diagnostic procedures from 2012 to 2017 were reviewed, and singleton pregnancies terminated following diagnosis of genetic abnormalities were identified. Cases diagnosed as the result of screening tests were compared with remaining cases. Conditions were considered "screened for" if they can be suspected by cell-free DNA testing, biochemistry, carrier screening, or if the patient was a known carrier of a single-gene disorder. When abnormal karyotype, microarray, or Noonan's syndrome was associated with abnormal NT, these cases were considered "screened for." GA at abortion was the primary outcome. Fisher's exact test and Mann-Whitney's U test were used for statistical comparison. Results In this study, 268 cases were included. A total of 227 (85%) of abortions were performed for "screened for" disorders, with 210 (93%) of these for karyotype abnormalities, 5 (2%) for microarray abnormalities, and 12 (5%) for single-gene disorders. Forty-one (15%) of abortions were performed for conditions not included in screening, with 8 (19%) of those for karyotype abnormalities, 25 (61%) for microarray abnormalities, and 8 (19%) for single-gene disorders. Invasive testing and abortion occurred at earlier median GA for those with conditions that were screened for: 12 2/7 versus 15 5/7 weeks, p ≤0.001 and 13 5/7 versus 20 0/7 weeks; p ≤0.001. Conclusion Most abortions were for abnormalities that can be suspected early in pregnancy. As many structural abnormalities associated with rare conditions are not identifiable until the mid-trimester, prenatal diagnosis and abortion occurred significantly later. Physicians and patients should be aware of the limitations of genetic screening.

Keywords: abortion; amniocentesis; chorionic villi sampling; chromosomal microarray; prenatal genetic screening; single gene disorders.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors do not have any conflict of interest.

Figures

Fig. 1
Fig. 1
Types of genetic disorders in the two study groups: abortions performed for “screened for” conditions and abortions performed for not “screened for” conditions.

Similar articles

Cited by

References

    1. Nussbaum R L, McInnes R R, Willard H F. Philadelphia, PA: Elsevier; 2016. Principles of clinical cytogenetics and genome analysis.
    1. Practice Bulletin No. 163 Summary: screening for fetal aneuploidy. Obstet Gynecol. 2016;127(05):979–981. - PubMed
    1. et al.SMFM statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am J Obstet Gynecol. 2015;213(06):753–754. - PubMed
    1. et al.Prenatal aneuploidy screening using cell-free DNA. Am J Obstet Gynecol. 2015;212(06):711–716. - PubMed
    1. Microarrays and next-generation sequencing technology: the use of advanced genetic diagnostic tools in obstetrics and gynecology. Obstet Gynecol. 2016;128(06):262–268. - PubMed